Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BioLineRx out-licenses HCV compound to Jiangsu Chia-Tai

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) granted Jiangsu Chia-Tai Tianqing Pharmaceutical Co. Ltd.

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE